Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Subscribe To Our Newsletter & Stay Updated
